Loading…
LPCN
Lipocine Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 53630X203
$2.17-2.69%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $17.89M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.8x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.85
- ROE
- -60.94%
- Profit margin
- 0.00%
- Revenue growth
- -69.50%
- Beta
- 0.46
- 52-week high
- $12.37
- 52-week low
- $1.81
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -88.1% over 5Y.
today you would have $113.33▼ -88.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 13 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.03 | $4.88 | $2.79 | $6.77 | $16.85 | $23.12 | $6.55 | $22.10 | $58.48 | $62.56 | $219.81 | $89.42 | $140.25 | |
| P/E | — | — | 3168.4x | — | — | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PMIPicard Medical, Inc. | $8.80 | — | 10.5x | — | — | $18.07M |
| BIVIBiovie Inc | $2.16 | — | 1.6x | — | -150.76% | $18.25M |
| TPSTTempest Therapeutics, Inc. | $1.06 | — | 18.6x | — | -931.14% | $17.53M |
| BCDABioCardia, Inc. | $1.15 |
About the company
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
- 14
- Salt Lake City, United States
Company description provided by Yahoo Finance.